Search results for "High-Throughput Nucleotide Sequencing"

showing 10 items of 224 documents

A Revised Timescale for Human Evolution Based on Ancient Mitochondrial Genomes

2013

Summary Background Recent analyses of de novo DNA mutations in modern humans have suggested a nuclear substitution rate that is approximately half that of previous estimates based on fossil calibration. This result has led to suggestions that major events in human evolution occurred far earlier than previously thought. Results Here, we use mitochondrial genome sequences from ten securely dated ancient modern humans spanning 40,000 years as calibration points for the mitochondrial clock, thus yielding a direct estimate of the mitochondrial substitution rate. Our clock yields mitochondrial divergence times that are in agreement with earlier estimates based on calibration points derived from e…

Mitochondrial DNATime Factorsancient modern humansMolecular Sequence DataPopulationancient modern humans; mitochondrial genome; mitochondrial clockBiologyGenomeArticleGeneral Biochemistry Genetics and Molecular BiologyEvolution Molecular03 medical and health sciences0302 clinical medicineHumanseducationancient DNA Human EvolutionPhylogenyDemography030304 developmental biologyGeneticsHuman mitochondrial molecular clock0303 health scienceseducation.field_of_studyBase SequenceModels GeneticAgricultural and Biological Sciences(all)FossilsGenome HumanBiochemistry Genetics and Molecular Biology(all)HaplotypeHigh-Throughput Nucleotide SequencingBayes TheoremHaplogroup L3mitochondrial clockHaplotypesHuman evolutionmitochondrial genomeGenome MitochondrialLinear ModelsHuman genomeGeneral Agricultural and Biological Sciences030217 neurology & neurosurgeryCurrent Biology
researchProduct

Novel mutations of the ABCA12, KRT1 and ST14 genes in three unrelated newborns showing congenital ichthyosis.

2022

Abstract Background Congenital ichthyosis (CI) is a heterogeneous group of genetic disorders characterized by generalized dry skin, scaling and hyperkeratosis, often associated to erythroderma. They are rare diseases, with overall incidence of 6.7 in 100,000. Clinical manifestations are due to mutations in genes mostly involved in skin barrier formation. Based on clinical presentation, CI is distinguished in non-syndromic and syndromic forms. To date, mutations of more than 50 genes have been associated to different types of CI. Cases presentation We report on three Italian unrelated newborns showing clinical signs compatible with different forms of CI of variable severity, namely Harlequin…

MutationSerine EndopeptidasesInfant NewbornHigh-Throughput Nucleotide SequencingHumansATP-Binding Cassette TransportersAlopeciaGeneral MedicineKeratin-1Congenital ichthyosis Target NGS Harlequin ichtyosis Epidermolytic ichtyosis Autosomal recessive ichtyosis with hypotrichosis Case reportIchthyosis LamellarItalian journal of pediatrics
researchProduct

Drug connectivity mapping and functional analysis reveal therapeutic small molecules that differentially modulate myelination

2022

Disruption or loss of oligodendrocytes (OLs) and myelin has devastating effects on CNS function and integrity, which occur in diverse neurological disorders, including Multiple Sclerosis (MS), Alzheimer’s disease and neuropsychiatric disorders. Hence, there is a need to develop new therapies that promote oligodendrocyte regeneration and myelin repair. A promising approach is drug repurposing, but most agents have potentially contrasting biological actions depending on the cellular context and their dose-dependent effects on intracellular pathways. Here, we have used a combined systems biology and neurobiological approach to identify compounds that exert positive and negative effects on olig…

MyelinMiceMyelin SheathNSC Neural stem cellSystems BiologyOPC Oligodendrocyte progenitor cellHigh-Throughput Nucleotide SequencingLINCS The Library of Integrated Network-based Cellular SignaturesCell DifferentiationGeneral MedicineCNS Central Nervous SystemOligodendrogliamedicine.anatomical_structureOligodendrogenesisNFOL Newly formed oligodendrocyteOL OligodendrocyteSignal TransductionSubventricular zoneOptic nerveIn silicoSystems biologyMorpholinesSVZ subventricular zoneContext (language use)RM1-950BiologyArticlemedicinePharmacogenomics The Library of Integrated Network-Based Cellular Signatures/LINCSAnimalsH-LY29 High concentration of LY294002Computer SimulationPI3K/AKT/mTOR pathwayL-LY29 Low concentration of LY294002PharmacologyPI3K/AktTCN TriciribineDose-Response Relationship DrugRegeneration (biology)Multiple sclerosismedicine.diseaseOligodendrocyteOligodendrocyteiNSCs iPSC-derived NSCsTAPs Transiently amplifying progenitorsMice Inbred C57BLMS Multiple SclerosisiPCS induced Pluripotent Stem CellChromonesPharmacogeneticsTherapeutics. PharmacologyMOL Myelinating oligodendrocyteNeuroscienceBiomedicine & Pharmacotherapy
researchProduct

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

2013

Background Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line. Results We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 and Mki67, are highly expressed while differentiation and top-crypt markers Muc2, Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53 (tp53), Mdm2, Hif1a, and Nras are highly expressed while Egfr and Flt1 are not. MHC class I but not MHC class…

Neuroblastoma RAS viral oncogene homologmedicine.disease_causeMajor histocompatibility complexPolymorphism Single NucleotideProto-Oncogene Proteins p21(ras)TranscriptomeMiceAntigenAntigens NeoplasmCDKN2ACell Line TumorMHC class ImedicineGeneticsAnimalsCancer modelsComputational immunologyCyclin-Dependent Kinase Inhibitor p16Mice Inbred BALB CMHC class IIbiologyCarcinomaHigh-Throughput Nucleotide SequencingSequence Analysis DNAColorectal cancerMolecular biologyColonic Neoplasmsbiology.proteinImmunotherapyKRASTranscriptomeResearch ArticleBiotechnologyBMC Genomics
researchProduct

Complete sequencing of Novosphingobium sp. PP1Y reveals a biotechnologically meaningful metabolic pattern.

2014

Background Novosphingobium sp. strain PP1Y is a marine α-proteobacterium adapted to grow at the water/fuel oil interface. It exploits the aromatic fraction of fuel oils as a carbon and energy source. PP1Y is able to grow on a wide range of mono-, poly- and heterocyclic aromatic hydrocarbons. Here, we report the complete functional annotation of the whole Novosphingobium genome. Results PP1Y genome analysis and its comparison with other Sphingomonadal genomes has yielded novel insights into the molecular basis of PP1Y’s phenotypic traits, such as its peculiar ability to encapsulate and degrade the aromatic fraction of fuel oils. In particular, we have identified and dissected several highly …

NovosphingobiumSphingomonadDe novo sequencing; Novosphingobium sp. PP1Y; Sphingomonads; Aromatic pollutant compounds/bioremediationAromatic pollutant compoundComputational biologyNovosphingobium sp. PP1YAromatic pollutant compounds/bioremediationGenomeSphingomonadsDNA sequencingDe novo sequencingbioremediationNext generation sequencingGeneticsPhylogenyWhole genome sequencingGeneticschemistry.chemical_classificationbiologyHigh-Throughput Nucleotide SequencingQuorum SensingSequence Analysis DNAbiology.organism_classificationSphingomonadaceaeSphingomonadaceaeQuorum sensingBiodegradation EnvironmentalchemistryGenes BacterialEnergy sourceAromatic hydrocarbonMetabolic Networks and PathwaysResearch ArticleBiotechnology
researchProduct

Integrative bioinformatics and omics data source interoperability in the next-generation sequencing era-Editorial.

2021

With the advent of high-throughput and next-generation sequencing (NGS) technologies [1], huge amounts of ‘omics’ data (i.e. data from genomics, proteomics, pharmacogenomics, metagenomics, etc.) are continuously produced. Combining and integrating diverse omics data types is important in order to investigate the molecular machinery of complex diseases, with the hope for better disease prevention and treatment [2]. Experimental data repositories of omics data are publicly available, with the main aim of fostering the cooperation among research groups and laboratories all over the world. However, despite their openness, the effective integrated use of available public sources is hampered by t…

Omics dataIntegrative bioinformaticsSettore INF/01 - InformaticaComputer scienceInteroperabilityComputational BiologyHigh-Throughput Nucleotide SequencingMolecular BiologyData sciencedata integration omics data sources interoperabilityDNA sequencingInformation SystemsBriefings in bioinformatics
researchProduct

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

2019

Background The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the …

OncologyGermline0302 clinical medicineLoss of Function MutationSurgical oncologyOdds RatioPrevalenceMissense mutation030212 general & internal medicineAge of Onset10. No inequalityExomeEarly onset breast cancerAged 80 and overOvarian NeoplasmsBARD1 GeneHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030220 oncology & carcinogenesisFemaleTechnology PlatformsResearch ArticleAdultmedicine.medical_specialtyAdolescentUbiquitin-Protein Ligases610Breast Neoplasmslcsh:RC254-282Young Adult03 medical and health sciencesGermline mutationBreast cancerOvarian cancerInternal medicinemedicineBARD1HumansGenetic Predisposition to DiseaseGermline mutationsGenetic Association StudiesGerm-Line MutationAgedbusiness.industryTumor Suppressor ProteinsOdds ratiomedicine.diseaseConfidence intervalBARD1; Early onset breast cancer; Germline mutations; Ovarian cancerOvarian cancerbusiness
researchProduct

Tumor mutational burden on cytological samples: A pilot study.

2020

Background Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor mutational burden (TMB-H). However, measuring TMB-H remains challenging for several reasons, among which is the difficulty in obtaining adequate tissue material from NSCLC patients. There are no data in the current literature regarding the possibility of adopting cell blocks (CBs) for T…

OncologyMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsCytological TechniquesDNA Mutational Analysis030209 endocrinology & metabolismPilot Projects03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerPredictive biomarkerAgedRetrospective Studiesnext generation sequencingTMBbusiness.industryAdvanced stageTreatment optionsHigh-Throughput Nucleotide SequencingIon semiconductor sequencingAmpliconmedicine.diseasePrognosislung cancerOncology030220 oncology & carcinogenesisMutationcytologyTissue materialFemaleimmunotherapyNon small cellbusinessFollow-Up StudiesCancer cytopathologyReferences
researchProduct

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy includi…

2015

Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.

OncologyMalemedicine.medical_treatmentarray-based comparative genomic hybridization (aCGH)Intensive chemotherapyKaplan-Meier EstimateBioinformatics0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy ProtocolsYoung adultComparative Genomic HybridizationGenomeArray-based comparative genomic hybridizationBurkitt lymphomaHigh-Throughput Nucleotide SequencingHematologyMiddle AgedPrognosisBurkitt Lymphomahumanities3. Good healthTreatment Outcome030220 oncology & carcinogenesisoutcomeRituximabFemaleRituximabmedicine.drugAdultmedicine.medical_specialtyAdolescenteducationBiologyNext-generation sequencing outcome03 medical and health sciencesYoung AdultInternal medicinemedicineHumansIn patientAgedChromosome AberrationsChemotherapymedicine.diseaseGNA13Lymphomastomatognathic diseasesnext-generation sequencing030215 immunologyComparative genomic hybridization
researchProduct

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

2015

Background: Evidence suggests that metastatic colorectal carcinoma (mCRC) has a high level of intratumor heterogeneity. We carried out a quantitative assessment of tumor heterogeneity for KRAS, NRAS, BRAF and PIK3CA mutations, in order to assess potential clinical implications. Patients and methods: Tumor samples (n = 182) from the CAPRI-GOIM trial of first-line cetuximab + FOLFIRI in KRAS exon-2 wild-type mCRC patients were assessed by next-generation sequencing that allows quantitative assessment of mutant genes. Mutant allelic frequency was normalized for the neoplastic cell content and, assuming that somatic mutations usually affect one allele, the Heterogeneity Score (HS) was calculate…

OncologyNeuroblastoma RAS viral oncogene homologOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabCetuximab; Colorectal cancer; Mutations; Next-generation sequencing; Tumor heterogeneity; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance Neoplasm; Fluorouracil; GTP Phosphohydrolases; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Hematology; OncologyColorectal Neoplasmmedicine.disease_causeGTP PhosphohydrolasesGTP PhosphohydrolasePhosphatidylinositol 3-KinasesGene FrequencyAntineoplastic Combined Chemotherapy ProtocolsMembrane ProteinClass I Phosphatidylinositol 3-KinasecolorectalCetuximabHigh-Throughput Nucleotide SequencingHematologyTreatment OutcomeOncologyFOLFIRIKRASFluorouracilColorectal Neoplasmsmedicine.drugHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyTumor heterogeneityClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Internal medicinemedicinecancerHumansneoplasmsAllele frequencyAntineoplastic Combined Chemotherapy ProtocolSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryCarcinomaOrganoplatinum CompoundMembrane ProteinsCancermedicine.diseaseColorectal cancerdigestive system diseasesDrug Resistance NeoplasmMutationCancer researchNext-generation sequencingNeoplastic cellCamptothecinPhosphatidylinositol 3-Kinasebusiness
researchProduct